Harvoni

Harvoni is a prescription oral tablet that combines 90 mg ledipasvir and 400 mg sofosbuvir. It belongs to the direct‑acting antiviral class and is indicated for the treatment of chronic hepatitis C virus (HCV) infection of genotypes 1, 4, 5 and 6 in the European market. The combination targets two distinct steps in the viral replication cycle, providing a pangenotypic option for patients who are treatment‑naïve or have prior therapy experience.

Harvoni is approved for several chronic hepatitis C indications, reflecting its activity against multiple genotypes.

- Treatment of chronic HCV genotype 1 infection in adults. - Treatment of chronic HCV genotype 4 infection. - Treatment of chronic HCV genotype 5 infection. - Treatment of chronic HCV genotype 6 infection. - Use in patients with compensated liver disease, including cirrhosis. - Option for both treatment‑naïve and treatment‑experienced individuals.

Adverse events reported with Harvoni vary in frequency; most are mild to moderate, while rare serious reactions may occur.

Common: - Fatigue - Headache - Nausea - Diarrhea

Serious: - Hepatic decompensation in patients with advanced cirrhosis - Severe allergic reactions such as rash or angioedema - Elevated serum transaminases

Clinicians should evaluate several safety considerations before initiating Harvoni therapy.

- Assess liver function; avoid use in patients with decompensated cirrhosis. - Review renal function; dose adjustment is not required but monitor in severe impairment. - Pregnancy status should be confirmed; safety data are limited. - Co‑administration with strong enzyme inducers may reduce efficacy. - Monitor for signs of hepatitis flare or hepatic failure during treatment. - Counsel patients on adherence to the full treatment course. - Evaluate for potential drug‑resistance mutations in prior therapy failures.

Harvoni interacts with several medicines that affect its absorption or antiviral activity.

Avoid: - Strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John’s wort. - Amiodarone (risk of serious bradycardia when co‑administered). - Antiretroviral agents that are potent inducers of P‑gp or BCRP.

Use with caution: - Antacids containing aluminum or magnesium; separate dosing by at least 4 hours. - Certain statins (e.g., simvastatin, lovastatin) due to increased exposure. - HIV protease inhibitors; monitor for possible pharmacokinetic changes.